XAGE (Longevity Health Holdings) EV-to-EBIT: -0.09 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XAGE Longevity Health Holdings Inc XAGE
6 GF Score
Price $0.21
! 3 Warning Signs
View Full Analysis

What is Longevity Health Holdings EV-to-EBIT?

Longevity Health Holdings XAGE 6 EV-to-EBIT is -0.09 as of Jul. 22, 2026. GuruFocus rates XAGE with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 1,559 Consumer Packaged Goods companies, Longevity Health Holdings ranks worse than 64143.62% on this metric.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Longevity Health Holdings's Enterprise Value is $0.61 Mil. Longevity Health Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.78 Mil. Therefore, Longevity Health Holdings's EV-to-EBIT for today is -0.09.

The historical rank and industry rank for Longevity Health Holdings's EV-to-EBIT or its related term are showing as below:

XAGE' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.35   Med: -0.27   Max: 0.04
Current: -0.09

During the past 5 years, the highest EV-to-EBIT of Longevity Health Holdings was 0.04. The lowest was -2.35. And the median was -0.27.

XAGE's EV-to-EBIT is ranked worse than
100% of 1559 companies
in the Consumer Packaged Goods industry
Industry Median: 12.05 vs XAGE: -0.09

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Longevity Health Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $0.81 Mil. Longevity Health Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.78 Mil. Longevity Health Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -834.85%.


Longevity Health Holdings  (OTCPK:XAGE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Longevity Health Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2026 ) =EBIT / Enterprise Value (Q: Mar. 2026 )
=-6.778/0.811878
=-834.85 %

Longevity Health Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $0.81 Mil.
Longevity Health Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Longevity Health Holdings EV-to-EBIT Related Terms


Longevity Health Holdings EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Longevity Health Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Health Holdings EV-to-EBIT Chart

Longevity Health Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-EBIT
0.00 0.00 -5.70 -0.59 -0.05

Longevity Health Holdings Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.41 -0.35 -0.13 -0.05 -0.12

XAGE vs SNBH, SKVI, PG: EV-to-EBIT Comparison

For the Household & Personal Products subindustry, Longevity Health Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longevity Health Holdings EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Longevity Health Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Longevity Health Holdings's EV-to-EBIT falls into.


XAGE
6GF Score
Longevity Health Holdings Inc XAGE
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longevity Health Holdings EV-to-EBIT Calculation

Longevity Health Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.610/-6.778
=-0.09

Longevity Health Holdings's current Enterprise Value is $0.61 Mil.
Longevity Health Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of -0.09 mean?
Longevity Health Holdings (XAGE) has a EV-to-EBIT of -0.09 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Longevity Health Holdings and its competitors. According to the industry distribution chart, Longevity Health Holdings ranks #999999 out of 1559 companies in the Consumer Packaged Goods industry.
Is Longevity Health Holdings' EV-to-EBIT too high?
Longevity Health Holdings' current EV-to-EBIT is -0.09. Based on the distribution chart, Longevity Health Holdings ranks #999999 out of 1559 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Longevity Health Holdings has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Longevity Health Holdings' EV-to-EBIT compare to SNBH and SKVI?
According to the Consumer Packaged Goods industry distribution chart, Longevity Health Holdings ranks #999999 out of 1559 companies for EV-to-EBIT. This places Longevity Health Holdings in the lower half of its industry. The industry median EV-to-EBIT is 12.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Consumer Packaged Goods company?
The median EV-to-EBIT among Consumer Packaged Goods companies is 12.05, based on 1,559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Longevity Health Holdings and its competitors. For the Consumer Packaged Goods industry, the median EV-to-EBIT is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longevity Health Holdings's current EV-to-EBIT is -0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Health Holdings stock overvalued right now?
Longevity Health Holdings (XAGE) has a current EV-to-EBIT of -0.09. The current EV-to-EBIT is -0.09. Longevity Health Holdings' overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Longevity Health Holdings (XAGE), the current EV-to-EBIT is -0.09 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Health Holdings Business Description

Address 2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Longevity Health Holdings Inc is a bio-aesthetics company focused on longevity and healthy aging. The company develops cosmetic skincare and haircare products designed to support skin and hair health, tailored to meet the technical requirements of professional care providers as well as retail consumers. Its product pipeline also includes regenerative bone and tissue healing solutions, although further research and development in this area has been paused. The company markets its cosmetic products in the United States through business-to-business, direct-to-consumer, and distributor sales channels.
6GF Score

Get the complete analysis for XAGE

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price